IGF1 and Parkinson disease: IGF-1 increase could be indicating an incipient cognitive decline in SZ patients since previous studies have shown a significant increase in IGF-1 in SZ patients in early stages of Alzheimer’s (AD) [64] and Parkinson’s diseases [65].